163 related articles for article (PubMed ID: 33536633)
1. Benefit with first-line ICIs in mesothelioma.
Romero D
Nat Rev Clin Oncol; 2021 Apr; 18(4):194. PubMed ID: 33536633
[No Abstract] [Full Text] [Related]
2. Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial.
Scherpereel A; Mazieres J; Greillier L; Lantuejoul S; Dô P; Bylicki O; Monnet I; Corre R; Audigier-Valette C; Locatelli-Sanchez M; Molinier O; Guisier F; Urban T; Ligeza-Poisson C; Planchard D; Amour E; Morin F; Moro-Sibilot D; Zalcman G;
Lancet Oncol; 2019 Feb; 20(2):239-253. PubMed ID: 30660609
[TBL] [Abstract][Full Text] [Related]
3. Nivolumab for the treatment of unresectable pleural mesothelioma.
Hotta K; Fujimoto N; Kozuki T; Aoe K; Kiura K
Expert Opin Biol Ther; 2020 Feb; 20(2):109-114. PubMed ID: 31825692
[No Abstract] [Full Text] [Related]
4. Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial.
Disselhorst MJ; Quispel-Janssen J; Lalezari F; Monkhorst K; de Vries JF; van der Noort V; Harms E; Burgers S; Baas P
Lancet Respir Med; 2019 Mar; 7(3):260-270. PubMed ID: 30660511
[TBL] [Abstract][Full Text] [Related]
5. Dual Checkpoint Blockade Takes Aim at Relapsed Mesothelioma.
Cancer Discov; 2017 Aug; 7(8):OF7. PubMed ID: 28592400
[TBL] [Abstract][Full Text] [Related]
6. Ipilimumab/Nivolumab-related Opsoclonus-Myoclonus-Ataxia Syndrome Variant in a Patient with Malignant Pleural Mesothelioma.
Maller B; Peguero E; Tanvetyanon T
J Immunother; 2018; 41(9):411-412. PubMed ID: 29742520
[TBL] [Abstract][Full Text] [Related]
7. Malignant mesothelioma clinical trial combines immunotherapy drugs.
Chatwal MS; Tanvetyanon T
Immunotherapy; 2018 Apr; 10(5):341-344. PubMed ID: 29473471
[TBL] [Abstract][Full Text] [Related]
8. Nivolumab Plus Ipilimumab Should Be the Standard of Care for First-Line Unresectable Epithelioid Mesothelioma.
Baas P
J Thorac Oncol; 2022 Jan; 17(1):30-33. PubMed ID: 34930609
[No Abstract] [Full Text] [Related]
9. Response to Ipilimumab and Nivolumab in a Patient With Malignant Peritoneal Mesothelioma.
Rizzolo A; Ah-Lan KC; Nu TNT; Alcindor T
Clin Colorectal Cancer; 2022 Dec; 21(4):371-374. PubMed ID: 36055919
[No Abstract] [Full Text] [Related]
10. Effectiveness of Nivolumab on Sarcomatoid Malignant Pleural Mesothelioma With Eosinophilia and Eosinophilic Pleural Effusion.
Yamazoe M; Ozasa H; Kim YH
J Thorac Oncol; 2019 Nov; 14(11):e251-e253. PubMed ID: 31668324
[No Abstract] [Full Text] [Related]
11. Immune checkpoint inhibitors in mesothelioma: a turning point.
Ceresoli GL; Pasello G
Lancet; 2021 Jan; 397(10272):348-349. PubMed ID: 33485463
[No Abstract] [Full Text] [Related]
12. Nivolumab for pediatric malignant peritoneal mesothelioma.
Yaman Ortaköylü M; İncesoy Özdemir S; Dinçaslan H; Taçyıldız N; Ünal AE; Soydal Ç; Fitöz ÖS; Ünal E
Pediatr Blood Cancer; 2023 Feb; 70(2):e29892. PubMed ID: 35851543
[No Abstract] [Full Text] [Related]
13. The therapeutic implications of the genomic analysis of malignant pleural mesothelioma.
Zauderer MG
Nat Commun; 2021 Mar; 12(1):1819. PubMed ID: 33753750
[TBL] [Abstract][Full Text] [Related]
14. Initial evaluation of nivolumab in patients with post-operative recurrence of malignant pleural mesothelioma.
Nakamura A; Kondo N; Nakamichi T; Kuroda A; Hashimoto M; Matsumoto S; Yokoi T; Kuribayashi K; Kijima T; Hasegawa S
Jpn J Clin Oncol; 2020 Aug; 50(8):920-925. PubMed ID: 32463095
[TBL] [Abstract][Full Text] [Related]
15. A Phase II Trial of First-Line Combination Chemotherapy With Cisplatin, Pemetrexed, and Nivolumab for Unresectable Malignant Pleural Mesothelioma: A Study Protocol.
Fujimoto N; Aoe K; Kozuki T; Oze I; Kato K; Kishimoto T; Hotta K
Clin Lung Cancer; 2018 Sep; 19(5):e705-e707. PubMed ID: 29853412
[TBL] [Abstract][Full Text] [Related]
16. [Not Available].
Mignard X; Chaabane N; Fallet V; Wislez M
Bull Cancer; 2018 Dec; 105 Suppl 1():S16-S23. PubMed ID: 30595194
[TBL] [Abstract][Full Text] [Related]
17. Immune Checkpoints Aberrations and Malignant Mesothelioma: Assessment of Prognostic Value and Evaluation of Therapeutic Potentials.
Mohamed H; Eltobgy M; Abdel-Rahman O
Anticancer Agents Med Chem; 2017; 17(9):1228-1233. PubMed ID: 28042777
[TBL] [Abstract][Full Text] [Related]
18. Systemic therapy options for malignant pleural mesothelioma beyond first-line therapy: a systematic review.
Abdel-Rahman O; Kelany M
Expert Rev Respir Med; 2015 Oct; 9(5):533-49. PubMed ID: 26366804
[TBL] [Abstract][Full Text] [Related]
19. Relapsed malignant pleural mesothelioma: An impressive response to Nivolumab monotherapy.
Costa-Martins S; Vicente I; Valente S
Pulmonology; 2022; 28(2):142-144. PubMed ID: 34801435
[No Abstract] [Full Text] [Related]
20. Is There Room for Second-Line Treatment of Pleural Malignant Mesothelioma?
Addeo A; Buffoni L; Di Maio M
JAMA Oncol; 2017 Sep; 3(9):1170-1171. PubMed ID: 28114625
[No Abstract] [Full Text] [Related]
[Next] [New Search]
